These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
638 related items for PubMed ID: 28061907
1. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S. Respir Res; 2017 Jan 06; 18(1):8. PubMed ID: 28061907 [Abstract] [Full Text] [Related]
2. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Respir Med; 2016 Nov 06; 120():16-24. PubMed ID: 27817811 [Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C. Respir Med; 2017 May 06; 126():105-115. PubMed ID: 28427541 [Abstract] [Full Text] [Related]
4. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ. Int J Chron Obstruct Pulmon Dis; 2018 May 06; 13():945-953. PubMed ID: 29606861 [Abstract] [Full Text] [Related]
5. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. Kerwin EM, Spangenthal S, Kollar C, St Rose E, Reisner C. Respir Res; 2018 Mar 05; 19(1):38. PubMed ID: 29506504 [Abstract] [Full Text] [Related]
6. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ. Adv Ther; 2019 Sep 05; 36(9):2434-2449. PubMed ID: 31267366 [Abstract] [Full Text] [Related]
7. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. Ferguson GT, Reisner C, Pearle J, DePetrillo P, Maes A, Martin UJ. Pulm Pharmacol Ther; 2018 Apr 05; 49():67-74. PubMed ID: 29567116 [Abstract] [Full Text] [Related]
8. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, Arora S, Siler TM, Siddiqui S, Darken P, Fischer T, Maes A, Golden M, Orevillo C, Reisner C. Chest; 2017 Feb 05; 151(2):340-357. PubMed ID: 27916620 [Abstract] [Full Text] [Related]
13. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C. Int J Chron Obstruct Pulmon Dis; 2020 Sep 02; 15():99-106. PubMed ID: 32021148 [Abstract] [Full Text] [Related]
15. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Martinez FJ, Fabbri LM, Ferguson GT, Orevillo C, Darken P, Martin UJ, Reisner C. Chest; 2017 Dec 02; 152(6):1169-1178. PubMed ID: 28720336 [Abstract] [Full Text] [Related]
16. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD. Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M. Ther Adv Respir Dis; 2019 Dec 02; 13():1753466619894502. PubMed ID: 31868101 [Abstract] [Full Text] [Related]
17. Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. Fakih F, Spangenthal S, Sigal B, Darken P, Maes A, Siddiqui S, Gillen M, Reisner C, Martin UJ. Respir Med; 2018 May 02; 138():74-80. PubMed ID: 29724397 [Abstract] [Full Text] [Related]
18. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ. Int J Chron Obstruct Pulmon Dis; 2018 May 02; 13():2969-2984. PubMed ID: 30310273 [Abstract] [Full Text] [Related]